ELECTRONIC HEALTH RECORD (EHR) ENHANCEMENTS FOR MARCH 15, 2016 SUMMARY
|
|
- Dale Phelps
- 6 years ago
- Views:
Transcription
1 ELECTRONIC HEALTH RECORD (EHR) ENHANCEMENTS FOR MARCH 15, 2016 SUMMARY Problem Opening PACS Images on ipads or ibooks has Been Fixed Changes have been made in PROD to enable user credentials to be passed through from PowerChart to Centricity seamlessly. Providers who are currently logging into Centricity on their devices will no longer have to when viewing their patient s images. This will also allow providers who use MACs/Androids to access their patients PACS images on their devices. Related Results in PowerPlans Currently related lab results can be found using Related Results when ordering selected single medication orders. For example, Warfarin will pull in INR results if the results are in the patient profile. We are going to carry this functionality forward to PowerPlans as well. Starting with the following blood transfusion PowerPlans for adults/paediatrics/neonates, related results will be linked to the plans. Blood transfusion - Packed Red Blood Cells = Hemoglobin Blood transfusion - Prothrombin Complex Concentrate INR based = INR Blood transfusion Plasma = INR Blood transfusion Platelets = THR (platelet count) Blood transfusion Cryoprecipitate = FIB (Fibrinogen level) Blood transfusion Factor VIIa recombinant = THR, INR/PTT, FIB P a g e 1
2 The number of related lab results to view will be indicated in ( ). Click Related Results to view results. P a g e 2
3 Paediatric Cardiology Studies at VH Only When the following orderables are ordered electronically you are no longer required to also send a paper requisition VH Cardiology. Area ECG Order ECG 12 Lead Pediatric ECG Pediatric Research ECG Research Resulted Pediatric ECG Signal Average Pediatric Echo Echo Fetal Echo Pediatric Holter Holter hrs Pediatric Holter hrs Pediatric Holter 60 hrs - 13 days Pediatric Holter Peds Research Loop Loop Recording 14+Days Pediatric Loop Recording 24-35hr Pediatric Loop Recording 36-59hr Pediatric Loop Recording 60hr-13 day Pediatric Stress Testing Stress Testing Pediatric Stress Testing Pediatric Metabolic Stress Testing Pediatric Research Stress Research Resulted Pediatric Stress Test Ped Metabolic Research LHSC Chargeable Items On March 30 th, 2016 Finance and ITS will complete the implementation of electronic ordering of chargeable items at LHSC. This electronic process replaces the current paper process in which the healthcare professional completes a paper invoice, has the patient sign it, and then sends the copies to the appropriate departments. P a g e 3
4 What Are Chargeable Items? Chargeable items are those governed by Corporate Policy FIN001- Charging of Uninsured Service, Supplies and Devices. Currently this policy is under review. Chargeable items are products and equipment, not included in OHIP coverage, which patients take home when discharged from the hospital. These include; crutches, splints, braces, abdominal binders, breast pumps, etc. Units and departments purchase these items, Finance then charges the patient after discharge and reimburses the unit/department. These charges may originate from any patient care area in the hospital, i.e., inpatient, outpatient, emergency, day surgery. How Are Chargeable Items Ordered and Invoiced Electronically? An electronic order and invoice process is used when the invoice will be $10 or greater. A regulated health professional assesses a patient and determines their product needs. They confirm the assessment with the patient, discuss the item cost, and confirm consent for the product. The consent is documented in the patient chart and an order is placed in Cerner on the patient s current encounter. Chargeable item orders can be found by: In Add Orders type charge in the Search field. In Add Order open the Patient Accounts order folder and look in the appropriate sub-folder(s). Setting up your own favorites of items you frequently provide. P a g e 4
5 *Important Orders that are used for chargeable items all have (charge) at the end of their name. ONLY use these orders when the product has been given to the patient. Once the order is placed, a message automatically goes to the Finance system identifying the item, quantity, and department/unit from which the item came. When the patient is discharged a bill is automatically generated and sent to the patient s current address. Once the bill is paid, the department/unit is reimbursed. Electronic Order Details All of the orderables have a similar layout. The Ordering Department is automatically set to the patient s registration location when ordered as blank. If the product originated from another unit or department, that location is selected from the field s drop-down menu. Communicating Costs to Patients To help encourage accurate communication of product costs, reference text is available for each of the items identifying the current cost charged by the hospital. This information can be accessed by clicking the paper icon on the orderable. P a g e 5
6 Opening the reference text will show the cost. What if the Item is NOT Needed When the Patient is Discharged? If the product is no longer needed, the healthcare professional will cancel the order in the Cerner system before the patient has been discharged. This will automatically send a message to Finance that the patient should no longer be charged. What if the Invoice is Less Than $10? When the invoice is less than $10 we do not charge electronically. In this scenario the patient can be charged directly. Documentation of these invoices needs to be completed and submitted to Finance through a paper process. Consult your leader regarding the paper process is for your area. What if the Item Does Not Appear in the Cerner System, but Should be Charged? Items for which a patient should pay, but are not available in the Cerner system, should be managed using the paper process. This means completing the paper charge slip and sending it to the Business Office. Finance will then follow-up with the patient. Processes for having new or replacement items added to the system are under development by the Finance Department. Cerner Downtime In a Cerner downtime situation the paper charge slip ( ) should be completed and sent to the Business Office. Back entry of these orders into Cerner should NOT occur as duplicate charges may be sent to the patient. P a g e 6
7 PowerForm Added to EMG Order (St. Joseph s Health Care Only) This change will affect the EMG referral for St. Joseph s Hospital and Parkwood Institute Main Building. The electromyography (EMG) order will now require a PowerForm to be completed that will improve the ordering process. Complete the PowerForm 1. You must complete all yellow fields as they are required to complete/sign the PowerForm. 2. Click the Sign icon (green check mark) in the upper left corner. 3. Complete any additional order details in the order window. 4. Click the Sign button to sign the order. Precaution Orders at St. Joseph s Precaution orders will be implemented starting March 1, for all inpatients and one-day stays. Precaution orders will allow us to electronically track, document and monitor the implementation and discontinuation of additional precautions in the organization in a consistent and timely manner. Any health care professional can initiate precaution orders. P a g e 7
8 Precaution Orders will: Identify patients requiring precautions electronically in PowerChart; Provide consistent communication of the need for precautions during patient stay and during transfer; Facilitate the tracking and monitoring of precautions of admitted patients; and Facilitate the tracking and monitoring of staff exposures to infections. Intermittent Medication Orders in PowerPlans You may encounter an error message when attempting to save PowerPlans containing Intermittent IV Medication Orders as favourites. We are aware of this issue and have been told that this issue will be resolved with our next code upgrade in September. Please check all favorite PowerPlans before signing to ensure your intermittent IV medication orders are ordered correctly. Please review the following list of medications for which this system error is seen. The following medications are currently flagged as intermittent in the Cerner system: BCG BCG 1.6 x 10*8 units-interferon alfa-2b 10,000,000 units BCG 1.6 x 10*8 units-interferon alfa-2b 20,000,000 units BCG 1.6 x 10*8 units-interferon alfa-2b 25,000,000 units BCG 2.67 x 10*8 units-interferon alfa-2b 10,000,000 units BCG 3.2 x 10*8 units-interferon alfa-2b 10,000,000 units BCG 4 x 10*8 units-interferon alfa-2b 10,000,000 units BCG 8 x 10*8 units-interferon alfa-2b 10,000,000 units CARBOplatin (onc) CARBOplatin (paeds) CISplatin (onc) CISplatin (paeds) CISplatin-cycloPHOSPHAMIDE-etoposide P a g e 8
9 CISplatin-mannitol DACTINomycin (onc) DACTINomycin (paeds) DAPTOmycin DAUNOrubicin (onc) DAUNOrubicin (paeds) DOCEtaxel (onc) DOCEtaxel (paeds) DOXOrubicin (onc) DOXOrubicin (paeds) DOXOrubicin liposomal (onc) EPIrubicin (onc) IDArubicin (onc) IDArubicin (paeds) Kadcyla trastuzumab emtansine (onc) PACLitaxel (onc) PANitumumab (onc) PEMEtrexed (onc) PERTuzumab (onc) Remicade TIGE50I acetazolamide acetylcysteine acyclovir aldesleukin (onc) aldesleukin (paeds) alemtuzumab alemtuzumab (onc) alemtuzumab (paeds) alteplase (tpa) amphotericin B ampicillin ampicillin injection amsacrine (onc) anti-thymocyte globulin (rabbit) arsenic trioxide arsenic trioxide (onc) arsenic trioxide (paeds) asparaginase Erwinia (onc) asparaginase Erwinia (paeds) asparaginase Escherichia coli (onc) asparaginase Escherichia coli (paeds) azacitidine (onc) P a g e 9
10 azacitidine (paeds) azithromycin basiliximab bendamustine (onc) bevacizumab (onc) bevacizumab (paeds) bleomycin (onc) bleomycin (paeds) blinatumomab (onc) blinatumomab (paeds) bortezomib (onc) bortezomib (paeds) brentuximab vedotin (onc) brentuximab vedotin (paeds) busulfan injection cabazitaxel (onc) calcium 1000 mg-magnesium 1000 mg calcium chloride calcium gluconate carfilzomib study carmustine (onc) carmustine (paeds) caspofungin cefazolin cefazolin -additive cefazolin 1 g-metronidazole 500 mg cefoxitin ceftazidime ceftriaxone cefuroxime injection cetuximab (onc) chloramphenicol cladribine (onc) cladribine (paeds) clindamycin clofarabine clofarabine (onc) clofarabine (paeds) cloxacillin cyclophosphamide (onc) cyclophosphamide (paeds) cyclophosphamide-mesna cytarabine (onc) P a g e 10
11 cytarabine (paeds) cytarabine-hydrocortisone 1 to less than 2 yrs cytarabine-hydrocortisone 2 to less than 3 yrs cytarabine-hydrocortisone 3 to less than 9 yrs cytarabine-hydrocortisone greater than 9 yrs cytarabine-hydrocortisone less than 1 yr dacarbazine (onc) dacarbazine (paeds) denosumab (onc) desmopressin dexamethasone dexamethasone (paeds) dexamethasone - additive dexamethasone 10 mg-granisetron 1 mg dexamethasone 10 mg-ondansetron 8 mg dexamethasone 20 mg-ondansetron 16 mg dexamethasone 20 mg-ondansetron 8 mg dexrazoxane (onc) dexrazoxane (paeds) dextrose 10% in water (D10W) bolus dextrose 5% in water (D5W) bolus dextrose 5% in water (int) dextrose 5%-sodium chloride 0.45% (int) dextrose 5%-sodium chloride 0.9% dextrose 5%-sodium chloride 0.9% (int) digoxin diluent dimenhydrinate injection dinutuximab (paeds) diphenhydramine enalaprilat eribulin (onc) erythromycin lactobionate etoposide etoposide (onc) etoposide (paeds) etoposide phosphate (onc) etoposide phosphate (paeds) filgrastim (paeds) fludarabine (onc) fludarabine (paeds) fluorouracil (onc) folic acid P a g e 11
12 fosaprepitant foscarnet furosemide (paeds) furosemide injection ganciclovir gemcitabine (onc) gemcitabine (paeds) gentamicin glycopyrrolate granisetron granisetron (paeds) hydralazine hydrocortisone hydrocortisone - additive hyoscine butylbromide ifosfamide (onc) ifosfamide (paeds) ifosfamide-mesna ifosfamide-mesna in 1000 ml dextrose 5%-sodium chloride 0.45% (int) ifosfamide-mesna in 1000 ml dextrose 5%-sodium chloride 0.9% (int) ifosfamide-mesna in 1000 ml sodium chloride 0.9% (int) ifosfamide-mesna in 50 ml dextrose 5%-sodium chloride 0.45% (int) infliximab interferon alfa-2b interferon alfa-2b (onc) ipilimumab (onc) irinotecan (onc) iron dextran iron sucrose ketorolac lactated ringers bolus leucovorin (onc) leucovorin (paeds) levofloxacin magnesium in 1000 ml dextrose 5%-sodium chloride 0.45% (int) magnesium sulfate (paeds) magnesium sulfate - additive magnesium sulfate 1 g-potassium chloride 20 mmol magnesium-mannitol-kcl in 1000 ml dextrose 5%-sodium chloride 0.45% (int) magnesium-mannitol-kcl in 1000 ml dextrose 5%-sodium chloride 0.9% (int) magnesium-mannitol-kcl in 1000 ml sodium chloride 0.9% (int) magnesium-potassium chloride in 1000 ml dextrose 5%-sodium chloride 0.9% (int) magnesium-potassium chloride in 1000 ml sodium chloride 0.9% (int) P a g e 12
13 magnesium-potassium chloride in 500 ml sodium chloride 0.9% (int) mannitol mannitol - additive mannitol in 1000 ml dextrose 5%-sodium chloride 0.45% (int) mannitol-potassium chloride in 1000 ml dextrose 5%-sodium chloride 0.45% (int) mannitol-potassium chloride in 1000 ml sodium chloride 0.9% (int) melphalan (onc) mesna (onc) mesna (paeds) methotrexate (onc) methotrexate (paeds) methotrexate-hydrocortisone 1 to less than 2 yrs methotrexate-hydrocortisone 2 to less than 3 yrs methotrexate-hydrocortisone 3 to less than 9 yrs methotrexate-hydrocortisone greater than 9 yrs methotrexate-hydrocortisone less than 1 yr methylprednisolone methylprednisolone sodium succinate metoclopramide injection metronidazole metronidazole mitoxantrone (onc) mitoxantrone (paeds) mitomycin (onc) nab-paclitaxel protein-bound Abraxane (onc) nelarabine (onc) nelarabine (paeds) obinutuzumab (onc) ondansetron ondansetron (paeds) oxaliplatin (onc) pamidronate (onc) pegaspargase (onc) penicillin G sodium phytonadione piperacillin-tazobactam plerixafor (onc) potassium chloride potassium chloride -additive potassium chloride 20 mmol in sodium chloride 0.9% 50 ml catheter syringe potassium chloride 40 mmol in sodium chloride 0.9% 50 ml catheter syringe potassium phosphate potassium phosphate (paeds) P a g e 13
14 potassium phosphate bolus in sodium chloride 0.9% (paed) potassium phosphate bolus in sodium chloride 0.9% central (paed, based on potassium content) potassium phosphate bolus in sodium chloride 0.9% peripheral (paed, based on potassium content) prednisone (paeds) raltitrexed (onc) rituximab rituximab (onc) rituximab (paeds) rifampin injection romidepsin (onc) sodium bicarbonate (onc) sodium bicarbonate (paeds) sodium chloride sodium chloride 0.45% (half normal saline) bolus sodium chloride 0.9% (int) sodium chloride 0.9% (normal saline) bolus sodium chloride 0.9% (normal saline) bolus (paeds) sodium chloride 0.9% syringe sodium phosphate streptozocin (onc) temsirolimus (onc) temsirolimus (paeds) teniposide (onc) ticarcillin-clavulanate tobramycin topotecan (onc) topotecan (paeds) trabectedin (onc) tranexamic acid trastuzumab (onc) triple intrathecal therapy (int) triple intrathecal therapy 1 to less than 2 yrs triple intrathecal therapy 2 to less than 3 yrs triple intrathecal therapy 3 to less than 9 yrs triple intrathecal therapy greater than 3 yrs triple intrathecal therapy greater than 9 yrs valproic acid vancomycin vinblastine (onc) vinblastine (paeds) vincristine (onc) vincristine (paeds) P a g e 14
15 vinorelbine (onc) vinorelbine (paeds) voriconazole P a g e 15
MEDICAL NECESSITY GUIDELINE
PAGE: 1 of 10 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
More informationGuidelines on Chemotherapy-induced Nausea and Vomiting in Pediatric Cancer Patients
Guidelines on Chemotherapy-induced Nausea Vomiting in Pediatric Cancer Patients COG Supportive Care Endorsed Guidelines Click here to see all the COG Supportive Care Endorsed Guidelines. DISCLAIMER For
More informationUse of Prophylactic Growth Factors and Antimicrobials in Elderly Patients with Cancer: A
Supportive Care in Cancer Use of Prophylactic Growth Factors and Antimicrobials in Elderly Patients with Cancer: A Systematic Review of the Medicare Database Romina Sosa, Shuling Li, Julia T. Molony, Jiannong
More informationVivida Health Specialty Pharmacy Drugs (Injectable) Prior-Authorization Requirements Effective 1/1/19
Vivida Health Specialty Pharmacy Drugs (Injectable) Prior-Authorization Requirements Effective 1/1/19 All Non-Par Provider Requests Requires Authorization Regardless of Service J0178 J0180 J0202 J0205
More informationPrimary malignant neoplasms, not lymphatic or hematopoietic. Secondary malignant neoplasms (i.e.metastatic) Malignant neoplasm, unknown site
Supplementary Table 1. ICD-9-CM codes used to define cancer ICD-9 Diagnosis code 140.xx-172.xx 174.xx-195.xx 196.xx 198.xx 199.xx 200.xx-208.xx Description Primary malignant neoplasms, not lymphatic or
More informationSubject: Palonosetron Hydrochloride (Aloxi )
09-J0000-87 Original Effective Date: 02/15/09 Reviewed: 07/09/14 Revised: 03/15/18 Subject: Palonosetron Hydrochloride (Aloxi ) THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION
More informationCommittee Approval Date: December 12, 2014 Next Review Date: July 2015
Medication Policy Manual Policy No: dru378 Topic: Akynzeo, netupitant/palonosetron Date of Origin: December 12, 2014 Committee Approval Date: December 12, 2014 Next Review Date: July 2015 Effective Date:
More informationHaematology, Oncology and Palliative Care Directorate.
Anticancer Treatment for Administration on the Somerset Mobile Chemotherapy Unit The table below details the suitability of different types of anticancer treatment for administration on the Somerset Mobile
More informationWest of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting
West of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting Definitions Acute nausea and vomiting Delayed nausea and vomiting Anticipatory nausea and vomiting Initial
More informationSubject: Fosnetupitant-Palonosetron (Akynzeo) IV
09-J3000-01 Original Effective Date: 06/15/18 Reviewed: 05/09/18 Revised: 01/01/19 Subject: Fosnetupitant-Palonosetron (Akynzeo) IV THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION,
More informationPart B payment for drugs in Medicare 0
Part B payment for drugs in Medicare 0 Introduction: The recent pilot proposal 1 on Part B drug payment from the Center for Medicare and Medicaid Innovation of CMS has met strong resistance 2 from the
More informationPart B payment for drugs in Medicare: Phase 1 of CMS s proposed pilot and its impact on oncology care
Part B payment for drugs in Medicare: Phase 1 of CMS s proposed pilot and its impact on oncology care Raina H. Jain, Stephen M. Schleicher, Coral L. Atoria, Peter B. Bach Executive Summary The recent pilot
More informationAdult Intravenous Systemic Anticancer Therapy (SACT) Section A. SUMMARY of SCHEME QIPP Reference
CA2 Nationally standardised Dose banding for Adult Intravenous Anticancer Therapy (SACT) Scheme Name CA2: Nationally Standardised Dose Banding for Adult Intravenous Systemic Anticancer Therapy (SACT) Section
More informationGuidelines for the Use of Anti-Emetics with Chemotherapy
Guidelines for the Use of Anti-Emetics with The purpose of this document is to provide guidance on the rational use of anti-emetics for prevention and treatment of chemotherapy-induced nausea and vomiting
More informationPart B payment for drugs in Medicare 0
Part B payment for drugs in Medicare 0 Introduction: The recent pilot proposal 1 on Part B drug payment from the Center for Medicare and Medicaid Innovation of CMS has met strong resistance 2 from the
More informationGuideline Update on Antiemetics
Guideline Update on Antiemetics Clinical Practice Guideline Special Announcements Please check www.asco.org/guidelines/antiemetics for current FDA alert(s) and safety announcement(s) on antiemetics 2 Introduction
More informationSubject: NK-1 receptor antagonist injectable therapy (Emend, Cinvanti, Varubi )
09-J2000-60 Original Effective Date: 06/15/16 Reviewed: 04/11/18 Revised: 01/01/19 Subject: NK-1 receptor antagonist injectable therapy (Emend, Cinvanti, Varubi ) THIS MEDICAL COVERAGE GUIDELINE IS NOT
More informationGUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY CLASSIFICATION
GUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY More than half of all cancer patients experience nausea or vomiting during the course of their treatment. If nausea or vomiting becomes severe enough,
More informationSCI. SickKids-Caribbean Initiative Enhancing Capacity for Care in Paediatric Cancer and Blood Disorders
1.0 Introduction The (SCI) is a not-for-profit collaboration between the Hospital for Sick Children (SickKids), Toronto, Canada, and seven Caribbean health care institutions across six countries that strive
More informationManagements of Chemotherpay Induded Nausea and Vomiting
REVIEW ARTICLE Managements of Chemotherpay Induded Nausea and Vomiting Department of Surgery, The Catholic University of Korea Sung Geun Kim 23 24 Sung Geun Kim Korean Journal of Clinical Oncology Summer
More informationExhibit B United States Patent Application 20020012663 Kind Code A1 Waksal, Harlan W. January 31, 2002 Treatment of refractory human tumors with epidermal growth factor receptor antagonists Abstract A
More informationThe following are J Code requirements
The following are J Code requirements J Codes 20610 Arthrocentesis, aspiration and/or injection; major joint or bursa (eg, shoulder, hip, knee joint, subacromial bursa) A9579 Injection, gadolinium based
More informationDOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) Therapy (AC-T) 261 CARBOplatin (AUC4-6) Monotherapy-21 days
Last updated Oct 17, 2018 Tumour Group Protocol Number Protocol Name on NCCP website Breast 200 Trastuzumab (IV) Monotherapy 21 days 201 Trastuzumab (IV) Monotherapy 7 days 202 DOCEtaxel Monotherapy 100mg/m2
More informationGuideline for Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients
Guideline for Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients POGO Antineoplastic Induced Nausea and Vomiting Guideline Development Panel: L.
More information1. Purpose Documentation Description.1 4. References 8 5. Cross-References.8 6. Development of the guideline.8
CLINICAL GUIDELINE For use in (clinical areas): For use by (staff groups): For use for (patients): Document owner: Status: Oncology/Haematology Unit (excluding Paediatrics) Oncologists, Haematologists,
More informationDescription The following are synthetic cannabinoids requiring prior authorization: dronabinol (Marinol, Syndros ), nabilone (Cesamet )
Clinical Policy: Nabilone (Cesamet), Dronabinol (Marinol, Syndros) Reference Number: CP.CPA.242 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important
More informationProtocol Number Tumour Group Protocol Name on NCCP website 22/02/ Lung Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy
Last Updated 22-Feb-18 Date of last update Protocol Number Tumour Group Protocol Name on NCCP website 22/02/2018 221 Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy 249 Gynaecology Intrathecal
More informationAPPHON/ROPPHA Guideline for the Prevention and Management of Chemotherapy Induced Nausea and Vomiting in Children with Cancer
APPHON/ROPPHA Guideline for the Prevention and Management of Chemotherapy Induced Nausea and Vomiting in Children with Cancer 5850/5980 University Avenue, PO Box 9700, Halifax, N.S. B3K 6R8 PEDIATRIC HEMATOLOGY/ONCOLOGY
More informationProtocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249
Last updated Feb 9, 2018 Revision due Protocol Name on NCCP website Tumour Group Protocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249 Two Day Etoposide CISplatin
More informationObjective: To provide a standard procedure for the recycling of unused medication and the disposal of medicines across all BCPFT Hospital sites.
WARDS/DEPARTMENTS By: 0 01/09/019 1 of 3 Objective: To provide a standard procedure for the recycling of unused medication and the disposal of medicines across all BCPFT Hospital sites. Scope: All Black
More informationPrevention and Management of chemo-and radiotherapy-induced nausea and vomiting
Prevention and Management of chemo-and radiotherapy-induced nausea and vomiting Focusing on the updated MASCC/ESMO guidelines Karin Jordan Department of Hematology and Oncology, University of Heidelberg
More informationCurrent and Emerging Therapeutic Options in the Management of Chemotherapy-Induced Nausea and Vomiting (CINV) Objectives
Current and Emerging Therapeutic Options in the Management of Chemotherapy-Induced Nausea and Vomiting (CINV) Susan Urba, M.D. University of Michigan Comprehensive Cancer Center Objectives Mechanisms of
More informationEmetogenicity level 1. Emetogenicity level 2
Emetogenicity level 1 15 mins Pre-Chemo Maxalon 10mg po During chemo and Post Chemo 3 days Maxalon10mg po 8 hourly Increase Maxalon 20mg po 8 hourly Change to Cyclizine 50mg po 8 hourly 3 days If nausea
More informationDRUG EXTRAVASATION. Vesicants. Irritants
DRUG EXTRAVASATION Vesicants Irritants Vesicants Antineoplastic drugs Amsacrine Dactinomycin Daunorubicin Docetaxel (rare) Doxorubicin Epirubicin Idarubicin Mechlorethamine Mitomycin Oxaliplatin (rare)
More informationTo help doctors give their patients the best possible care, the American
Patient Information Resources from ASCO What to Know ASCO s Guideline on Preventing Vomiting Caused by Cancer Treatment SEPTEMBER 2011 KEY MESSAGES The risk of nausea and vomiting depends on the specific
More informationVI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Etiologies:
VI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Incidence: The incidence of acute and delayed N&V was investigated in highly and moderately emetogenic
More informationAdverse effects of anticancer drugs (Antimetabolites agents, Alkylating agents, Antimicrotubule agents, Miscellaneous agents, Immune therapies and
35 Adverse effects of anticancer drugs (Antimetabolites agents, Alkylating agents, Antimicrotubule agents, Miscellaneous agents, Immune therapies and Biologically directed therapies ) 1 1- Nausea and vomiting
More informationMASCC Guidelines for Antiemetic control: An update
MASCC / ISOO 17 th International Symposium Supportive Care in Cancer June 30 July 2, 2005 / Geneva, Switzerland MASCC Guidelines for Antiemetic control: An update Sussanne Börjeson, RN, PhD Linköping University,
More informationCOST CONSIDERATIONS Union for International Cancer Control 2014 Review of Cancer Medicines on the WHO List of Essential Medicines!!!!!!!!!
UICCEMLCostingScenarios BackoftheEnvelope Calculations PreparedforWorkingGroupSession:19621November2014,Geneva MethodsSummary We have chosen a conservative approach, calculating cost per vial. We have
More informationANTIEMETICS UTILIZATION MANAGEMENT CRITERIA
ANTIEMETICS [Akynzeo, Anzemet, Cesamet, Emend, Sancuso, Varubi, Zuplenz ] DRUG CLASS: UTILIZATION MANAGEMENT CRITERIA 5-HT 3 Receptor Antagonists 5-HT 3 Receptor Antagonist and Substance P/Neurokinin (NK
More informationDME MAC Jurisdiction C Drug Fees, Pharmacy Dispensing Fees and Pharmacy Supply Fees Effective 01/01/2018 through 03/31/2018
G0333 PHARMACY DISPENSING FEE FOR INHALATION DRUG(S); INITIAL 30-DAY SUPPLY AS A BENEFICIARY $57.000 J0133 INJECTION, ACYCLOVIR 5 MG $0.068 J0285 INJECTION, AMPHOTERICIN B 50 MG $32.987 J0287 INJECTION,
More informationDME MAC Jurisdiction B Drug Fees, Pharmacy Dispensing Fees and Pharmacy Supply Fees Effective 01/01/2019 through 03/31/2019
G0333 PHARMACY DISPENSING FEE FOR INHALATION DRUG(S); INITIAL 30-DAY SUPPLY AS A BENEFICIARY $57.000 J0133 INJECTION, ACYCLOVIR 5 MG $0.048 J0285 INJECTION, AMPHOTERICIN B 50 MG $31.668 J0287 INJECTION,
More informationJ1556 INJECTION, IMMUNE GLOBULIN (BIVIGAM) 500 MG $ J1559 INJECTION, IMMUNE GLOBULIN (HIZENTRA) 100 MG $14.364
G0333 INITIAL 30-DAY SUPPLY AS A BENEFICIARY $57.000 J0133 INJECTION, ACYCLOVIR 5 MG $0.470 J0285 INJECTION, AMPHOTERICIN B 50 MG $10.280 J0287 INJECTION, AMPHOTERICIN B LIPID COMPLEX 10 MG $21.850 J0288
More informationGuidelines for prevention and management of CHEMOTHERAPY EXTRAVASATION
Guidelines for prevention and management of CHEMOTHERAPY EXTRAVASATION Please note that this policy refers to the management of extravasation of cytotoxic chemotherapy only. Refer to local Trust policies
More informationICON Formulary - October 2018 Legend - ICON Protocols Essential (previously Standard), Core, Enhanced Core, Enhanced Enhanced
ICON Formulary - October 2018 Legend - ICON Protocols Essential (previously Standard), Core, Enhanced Core, Enhanced Enhanced Class Medicine Name Nappi Strength Form Size Route Abiraterone Acetate ZYTIGA
More informationThe AngCN Antiemetic Guidelines
The AngCN Antiemetic Guidelines Guidelines for the Management of Nausea and Vomiting in Adult Patients Receiving Chemotherapy and/or Radiotherapy AngCN Document Reference: AngCN-CCG-C31 CONTENTS 1.0 Introduction
More informationTitle Developed By. Implementation Contact person(s) Review Date Group Responsible. NICaN Policy: Management of Chemotherapy Extravasation; Version 3
Title Developed By Management of Chemotherapy Extravasation NICaN Regional Pharmacy Group Version History Version 3: 2009 (See appendix 6) Version 2: January 2006 Version 1: June 2005 Consultation Period
More informationCURRENT DRUG SHORTAGES (through February 22, 2013) CURRENT & ONGOING SHORTAGES CRITICAL SHORTAGES
CURRENT DRUG SHORTAGES (through February 22, 2013) CRITICAL SHORTAGES Acetylcysteine Inhalation Analgesic Buprenorphine Caffeine and Ergotamine Acyclovir Meperidine Injection Adenosine Amino Acid Products
More informationHigh Risk Medications
Department Policy Code: D: MM-5705 Entity: Fairview Health Services Department: Home Infusion Manual: Policies & Procedures Category: Medication Management Subject: High Risk Medications Purpose: To provide
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.CPA.223 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory
More informationNorthern Cancer Alliance
Northern Cancer Alliance Anti-emetic Guidelines for Chemotherapy Induced Nausea and Vomiting (CINV) Adult Oncology & Haematology Document Control Document Title: Antiemetic Guidelines for CINV NESCN v2.2
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Zofran, Zuplenz) Reference Number: CP.CPA.173 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this
More informationCPT Service Description Effective Date
Medical Oncology Program Review Code List 2 nd Quarter 2018 This list is subject to change once per quarter. Changes will be posted to the BCBSNC website at www.bcbsnc.com by the 10th day of January, April,
More informationECN Protocol Book. Guidelines on the management of extravasation. ECN_Protocol_Book_extravasation guidelines_2
ECN Protocol Book Guidelines on the management of extravasation Name of person presenting document: Reason for document development: Names of development team: Specify groups of staff to whom the document
More informationGuidelines for the Management of Extravasation (Version 5 May 2012)
Guidelines for the Management of Extravasation (Version 5 May 2012) Quality and safety for every patient every time Document Control Prepared By Chemo Nurse Group Chemo Nurse Group/ South Tees FT NECDAG
More informationCorporate Medical Policy
Antiemetic Injection Therapy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: antiemetic_injection_therapy 5/2015 3/2017 3/2018 3/2017 Description of Procedure
More informationAdjuvant/Curative/Neo-adjuvant High Grade and Burkitt s Lymphoma Regimens. High Grade Lymphoma
Adjuvant/Curative/Neo-adjuvant High Grade and Burkitt s Lymphoma Regimens The following table lists the evidence-informed regimens (both IV and non-iv) for high grade and Burkitt s lymphoma used in the
More informationTable III: 2019 Medicare Drug Fee Schedule* CY st Quarter Average Sales Price (ASP) Data Plus 6 Percent
Table III: 2019 Medicare Drug Fee Schedule* CY 2019 1st Quarter Average Sales Price (ASP) Data Plus 6 Percent *The Medicare payments allowance limits are effective Jan. 1 thru March. 31, 2019. CY 2019
More information1 The Cancer Programs Regulation (AR 242/98) is amended by this Regulation.
Alberta Regulation 18/2005 Cancer Programs Act AMENDMENT REGULATION Filed: February 22, 2005 For information only: Made by the Minister of Health and Wellness (M.O. 9/2005) on February 17, 2005 pursuant
More informationCHEMOTHERAPY NETWORK GROUP POLICY FOR THE MANAGEMENT
CHEMOTHERAPY NETWORK GROUP POLICY FOR THE MANAGEMENT OF ETRAVASATION Policy for the management of extravasation Contents Page number Introduction 3 Definition 3 Prevention 3 Follow up 6 Signs and symptoms
More informationAntiemetic Guidelines. Guidelines for the Management of Nausea and Vomiting in Adult Patients Receiving Chemotherapy and/or Radiotherapy
Antiemetic Guidelines Guidelines for the Management of Nausea and Vomiting in Adult Patients Receiving Chemotherapy and/or Radiotherapy For approvals and version control see Document Management Record
More informationDRUG PROPERTIES YOU NEED TO KNOW
Dr. Janet Fitzakerley Summer 2013 Med 6541 Hematopoiesis and Host Defences jfitzake@d.umn.edu www.d.umn.edu/~jfitzake Page 1 of 11 DRUG PROPERTIES YOU NEED TO KNOW 1. Mechanism of action a. chemical class
More informationContents Trials. Dose guidelines. Calvert formula Issue Date: January Author: No: Copy. Pagee 1 of 21. Issue.
Chapter 1: General information Contents Chapter 1: General information... 1 General observations... 2 Protocol Additions 2013... 2 Cancer Drugs Fund... 2 Off Protocol Treatment Policy... 2 Trials... 2
More informationINJECTION, INOTUZUMAB OZOGAMICIN, 0.1 MG [BESPONSA ] [C CODES FOR FACILITY USE ONLY]
Commercial Medical Oncology Program Review Code List 3rd Quarter 2018 This list is subject to change once per quarter. Changes will be posted to the BCBSNC website at www.bcbsnc.com by the 10th day of
More informationintolerance to, contraindication to, or therapeutic failure on a minimum 3 month trial of Inflectra*
What s New Medical Pharmaceutical Policy March 2018 Updates MBP 5.0 Remicade (infliximab), Inflectra (infliximab-dyyb), Renflexis (infliximab-abda)- Updated policy Remicade (infliximab), Inflectra (infliximab-dyyb)
More informationSupportive care session 1:
Board review in oncology pharmacy 2013 Managing Disease or Treatment Related Complication Supportive care session 1: Chemotherapy induced-nausea and vomiting Suthan Chanthawong, B. Pharm, RPh. Objectives
More informationChemotherapy induced emesis: Are we doing are best? David Warr University of Toronto
Chemotherapy induced emesis: Are we doing are best? David Warr University of Toronto david.warr@uhn.on.ca Conflict of interest Merck: speakers bureau and consultant Eisai: consultant Outline What is the
More informationJob title: Consultant Pharmacist/Advanced Practice Pharmacist
Title : Guidelines for the Use of Antiemetics Purpose: To provide trust-wide guidance on the safe and effective use of antiemetics for the prevention and treatment of chemotherapy and radiotherapy induced
More informationChemotherapy extravasation guideline
Chemotherapy extravasation guideline. written by: WOSCAN Cancer Nursing and Pharmacy Group date written: September 2009 approved by: West of Scotland Cancer Advisory Network Clinical Leads Group review
More informationGuidelines for the Management of Extravasation
Guidelines for the Management of Extravasation (Version 5.5-04 Nov 2016) Quality and safety for every patient every time Document Control Prepared By Chemo Nurse Group Chemo Nurse Group/ South Tees FT
More informationONCOLOGY AND HAEMATOLOGY TREATMENT CENTRE Quality System Guidelines For The Safe Delivery of Systemic Anti Cancer Therapy
Title Document Type Issue no Safe Delivery of Systemic Anti-Cancer Therapy Guideline Clinical Governance Support Team Use Issue date May 2014 Review date May 2016 Distribution Prepared by Developed by
More informationRelease of the 2017/18 Invitation to Tender
2 November 2017 Release of the 2017/18 Invitation to Tender The 2017/18 Invitation to Tender (2017/18 ITT) has been distributed today. If you have already registered your e-mail address with PHARMAC s
More informationChemotherapy Induced Nausea and Vomiting (CINV) Anti-emetic Guidelines
North of England Cancer Network Chemotherapy Induced Nausea and Vomiting (CINV) Anti-emetic Guidelines Adult Oncology & Haematology Quality and safety for every patient every time For more information
More informationANAPLASTIC LARGE CELL LYMPHOMA TREATMENT ROAD MAP (Modified ALCL99)
ANAPLASTIC LARGE CELL LYMPHOMA TREATMENT ROAD MAP (Modified ALCL99) CLASSIFICATION OF TREATMENT GROUPS: 1. Isolated Skin lesions, < 5 skin lesions. Treatment course: ( No treatment, wait and see approach)
More informationClinical Tools and Resources for Self-Study and Patient Education
Clinical Tools and Resources for Self-Study and Patient Education CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING CLINICIAN'S RESOURCE GUIDE The clinical tools and resources contained herein are provided as educational
More informationRecognising and reducing the risk of chemotherapy extravasation
Recognising and reducing the risk of chemotherapy extravasation When chemotherapy drugs leak from the veins it can cause serious injury to the patient, greatly heighten their fears of undergoing future
More informationHodgkin and Non-Hodgkin Lymphoma (LYM) Post-Infusion Data
Hodgkin and Non-Hodgkin Lymphoma (LYM) Post-Infusion Data Registry Use Only Sequence Number: Date Received: CIBMTR Center Number: CIBMTR Research ID: Event date: / / Visit 100 day 6 months 1 year 2 years
More information1 SpringerWienNewYork
1 SpringerWienNewYork I. Mader, P. R. Fürst-Weger, R. M. Mader, E. Nogler-Semenitz, S. Wassertheurer Extravasation of Cytotoxic Agents Compendium for Prevention and Management Second edition SpringerWienNewYork
More informationFOR A HIGHER DEGREE OF CONFIDENCE
SELECTING THE RIGHT HAND PROTECTION WHEN WORKING WITH CHEMOTHERAPY DRUGS. > Introduction Manufacturing specialized products in a pharmaceutical manufacturing environment has a specific set of requirements
More informationHazardous Medication List
Hazardous Medication List REDUCING OCCUPATIONAL EXPOSURE TO HAZARDOUS MEDICATION FOR ALL STAFF Table of Contents Hazardous Medication List Key Points... 1 Hazardous Medication List... 2 Special Handling
More informationCancer: Can we Afford the Cure? Current Trends in Oncology Treatment
Cancer: Can we Afford the Cure? Current Trends in Oncology Treatment Julie Kennerly-Shah, PharmD, MS, MHA, BCPS May 30, 2018 The Ohio State University Comprehensive Cancer Center Arthur G. James Cancer
More informationTrust Guideline for Prevention and Control of Chemotherapy and Radiotherapy Induced Nausea and Vomiting in Adults
A Clinical Guideline For Use in: Organisation-wide By: For: Key words: Name of document author: Job title of document author: Name of document author s Line Manager: Job title of author s Line Manager:
More informationClinical Policy: Aprepitant (Emend) Reference Number: CP.PMN.19 Effective Date: 11/06 Last Review Date: 08/17
Clinical Policy: (Emend) Reference Number: CP.PMN.19 Effective Date: 11/06 Last Review Date: 08/17 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationChemotherapy-induced Nausea and Vomiting: The Pharmacist s Role in Integrating Clinical Guidelines into Patient Care
Chemotherapy-induced Nausea and Vomiting: The Pharmacist s Role in Integrating Clinical Guidelines into Patient Care Presented as a Live Webinar Wednesday, April 13, 2016 12:00 p.m. 1:00 p.m. ET Tuesday,
More informationAD regimen, 576 adrenal steroid inhibitor. aminoglutethimide, 23 25
A 640 Index Index abiraterone acetate, 5 7 Abraxane. See albuminbound paclitaxel ABVD regimen, 57, 540 ABV regimen, 519 520 AC docetaxel regimen, 476, 478 acetaminophen busulfan and, 71 AC regimen, 475,
More informationAntiemetics: Guidelines, Interactions and more.
Antiemetics: Guidelines, Interactions and more. Chemotherapy-induced side effects -the patient s view Loss of hair The thought of coming for chemo Affects family/partner Affects work/home duties Jude Lees
More informationSTOP! Have you got the most up to date version of this policy? Always Check before reading further.
Network Guidance for the Prevention and Management of Cytotoxic Extravasation Injuries (October 09) STOP! Have you got the most up to date version of this policy? Always Check www.wales.nhs.uk/nwcn/ before
More informationFor Health Professionals Who Care For Cancer Patients EDITOR S CHOICE
Inside This Issue: For Health Professionals Who Care For Cancer s March 2019 Vol. 22 No. 3 Editor s Choice New Programs: Rituximab Protocols in CLL/SLL Updated (LYCLLBENDR, LYCLLCHLR, LYCLLCVPR, LYCLLFLUDR,
More informationOVERVIEW OF COMMENTS RECEIVED ON LIST OF PAEDIATRIC NEEDS ONCOLOGY I (CYTOTOXIC THERAPY)
European Medicines Agency Evaluation of Medicines for Human Use London, September 2006 Doc. Ref. OVERVIEW OF COMMENTS RECEIVED ON LIST OF PAEDIATRIC NEEDS ONCOLOGY I (CYTOTOXIC THERAPY) Table 1: Organisations
More informationHCPCS Code/ generic (Brand) Name J7506. J8520 capecitabine (Xeloda) 1. J8521 capecitabine. J8530 cyclophosphamide. (Cytoxan) 1
drug and administration compendia Current Price () J7506 Prednisone, oral, per 5 mg 12/1/07 $0.07 $0.19 N/A prednisone 2 J8520 capecitabine (Xeloda) 1 Capecitabine, oral, 150 mg 8/1/07 $5.79 $4.59 N/A
More informationAcute Lymphocytic Leukemia
Acute Lymphocytic Leukemia Splenectomy (Removal of Spleen) 6-Mercaptopurine (Purinethol, 6-MP) Alemtuzumab (Campath ) Arsenic Trioxide (Trisenox ) Bendamustine (Treanda ) Bexarotene (Targretin ) Bleomycin
More informationSURVEY SUL CONFLITTO DI INTERESSE IN ONCOLOGIA PROMOSSO DAL CIPOMO 1-31 MARZO. PARTECIPATE TUTTI nicsonet.it
SURVEY SUL CONFLITTO DI INTERESSE IN ONCOLOGIA PROMOSSO DAL CIPOMO 1-31 MARZO PARTECIPATE TUTTI www.cipomo.it; nicsonet.it LINEE GUIDA AIOM: LA TERAPIA ANTIEMETICA Fausto Roila S.C. Oncologia Medica, Terni
More informationREVIEW Guideline for the Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients
Pediatr Blood Cancer 2011;57:191 198 REVIEW Guideline for the Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients L. Lee Dupuis, MScPhm, ACPR, FCSHP,
More informationTransitioning Inpatient Chemotherapy to the Outpatient Setting
Transitioning Inpatient Chemotherapy to the Outpatient Setting A L I M C B R I D E, P H A R M D, M S, B C P S, B C O P C L I N I C A L C O O R D I N A T O R, T H E U N I V E R S I T Y O F A R I Z O N A
More informationDisclosure. Objectives. Objectives. Oncologic Emergency. Classification of Emergencies 1 3/2/2015
Disclosure Oncologic Emergencies and Acute Supportive Care of the Critically Ill Oncology Patient By: Kimberly Regis, Pharm.D. Broward Health Medical Center Pharmacy Resident 2014-2015 I do not have a
More informationSELECTING THE RIGHT HAND PROTECTION WHEN WORKING WITH CHEMOTHERAPY DRUGS
SELECTING THE RIGHT HAND PROTECTION WHEN WORKING WITH CHEMOTHERAPY DRUGS SELECTING THE RIGHT HAND PROTECTION WHEN WORKING WITH CHEMOTHERAPY DRUGS Manufacturing specialized products in a pharmaceutical
More informationClinical Policy: Dolasetron (Anzemet) Reference Number: ERX.NPA.83 Effective Date:
Clinical Policy: (Anzemet) Reference Number: ERX.NPA.83 Effective Date: 09.01.18 Last Review Date: 08.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationInpatient Antineoplastic Medication Administration And Associated Drug Costs: Institution of a Hospital Policy Limiting Inpatient Administration
Inpatient Antineoplastic Medication Administration And Associated Drug Costs: Institution of a Hospital Policy Limiting Inpatient Administration Alexandra E. Foster, PharmD; and David J. Reeves, PharmD,
More information